-
Article
Open AccessPublisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
-
Article
Open AccessSystemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective
Urothelial carcinoma (UC) is a common cancer associated with a poor prognosis in patients with advanced disease. Platinum-based chemotherapy has remained the cornerstone of systemic anticancer treatment for ma...
-
Article
Open AccessFirst-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose) polymerase. This association provides a rationale f...
-
Article
Open AccessA Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
Surgery for renal cell carcinoma (RCC) with venous tumour thrombus (VTT) extension into the renal vein (RV) and/or inferior vena cava (IVC) has high peri-surgical morbidity/mortality. NAXIVA assessed the respo...
-
Article
Open AccessMitigation of SARS-CoV-2 transmission at a large public university
In Fall 2020, universities saw extensive transmission of SARS-CoV-2 among their populations, threatening health of the university and surrounding communities, and viability of in-person instruction. Here we re...
-
Article
Open AccessHealthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
The aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chem...
-
Article
Open AccessEvaluating cancer research impact: lessons and examples from existing reviews on approaches to research impact assessment
Performing cancer research relies on substantial financial investment, and contributions in time and effort from patients. It is therefore important that this research has real life impacts which are properly ...
-
Article
Open AccessThe implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial
The utility of patient screening logs and their impact on improving trial recruitment rates are unclear. We conducted a retrospective exploratory analysis of screening data collected within a multicentre rando...
-
Chapter
Neoadjuvant vs. Adjuvant Chemotherapy: Which Is Right?
Muscle invasive bladder cancer which has not yet spread outside the bladder presents a very high risk of subsequent death from metastatic disease. It also presents the opportunity to cure by aggressive, multim...
-
Chapter
The Role of Medical Oncologist
The current position of the medical oncologist is clear in those patients who have metastatic disease at the time of diagnosis, or who develop metastatic disease following radical treatment. However, the role ...
-
Article
Open AccessProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
Background Docetaxel and prednisolone chemotherapy (DP) extends survival in metastatic castration resistant prostate cancer (mCRPC). However, emergent clinical resistance is almost inevitable. AK...
-
Article
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer
Prostate-specific antigen (PSA) decline by 50 % from the baseline to 12 weeks (PSA50w12) is currently used to predict response to treatment and clinical outcome of patients with metastatic castration-resistant...
-
Article
Open AccessNuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients
8000 cases of renal cancer are diagnosed each year in the UK, with a five-year survival rate of 50 %. Treatment options are limited; a potential therapeutic target is the Src family kinases (SFKs). SFKs have r...
-
Chapter
Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate
The combination of docetaxel with prednisone was the first treatment to demonstrate survival advantage in men with metastatic castration resistant prostate cancer (mCRPC) in 2004. Since then many investigators...
-
Article
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
Background: ASP9521 is a first-in-class orally available inhibitor of the enzyme 17 β-hydroxysteroid dehydrogenase type 5 (17 βHSD5; AKR1C3), catalysing the conversion of dehydroepiandros...
-
Article
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma
Combination chemotherapy regimens can improve survival in patients with advanced gastric and oesophageal adenocarcinoma. Docosahexaenoic acid (DHA)-paclitaxel is a novel conjugate formed by the covalent linkag...
-
Article
Focused Foster Care for Children with Serious Sexual Behavior Problems
Properly implemented, foster family care may represent a uniquely appropriate placement/treatment alternative for young children with pronounced or dangerous sexual behavior problems. A few programs have repor...
-
Article
8th International Conference: Primary Therapy of Early Breast Cancer, St Gallen, Switzerland, March 12–15 2003
The International St Gallen Breast Cancer Conference concentrates almost exclusively on adjuvant, multimodal primary therapy for early breast cancer. Begun 25 years ago, this meeting was initially held every 4...
-
Article
Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling
Although Src expression and activity are often elevated in colon cancer1,2,3, the precise consequences of overexpression of the non-catalytic Src homology (SH) domains, or enhanced catalytic activity, are unknown...
-
Article
Tracking the Sexual Behavior-Specific Effects of a Foster Family Treatment Program for Children with Serious Sexual Behavior Problems
Few treatment programs exist for very young children with serious sexual behavior problems. Fewer still have produced data relating to their effectiveness, and the sparse data that have emerged have focused on...
